2026-05-27T20:39:07Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/257492026-02-03T12:26:44Zcom_10630_2254col_10630_37959

Vidal-Valenzuela, Isabel Fernández-Florido, Elena Marrero Capitán, Ana Dácil Castilla, Laura Rodríguez-Quesada, Ana María Martínez-Póveda, Beatriz Amparo Medina-Torres, Miguel Ángel 2023-01-17T08:42:10Z 2023-01-17T08:42:10Z 2022 https://hdl.handle.net/10630/25749 Dimethyl itaconate (DMI) is a cell-permeable derivative of itaconate, a known immunomodulator metabolite synthesized from the Krebs cycle intermediate cis-aconitate by the enzyme aconitate dehydrogenase. Although DMI is not metabolized into itaconate intracellularly, immunomodulatory, anti-inflammatory and anti-oxidative effects has been described for this compound. Some of these processes affected by DMI are directly related to angiogenesis; however, nothing has been published yet in this field. The aim of this work is to evaluate the potential effect of DMI in different key steps of the angiogenic process. eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Angiogénesis The immunomodulator dimethyl taconite inhibits several key steps of angiogenesis in cultured endothelial cells conference output